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Biventricular pacing (BiV) is established as the primary modality to achieve cardiac 
resynchronization therapy (CRT), although non-response rates approach 30-40% (1). His bundle 
pacing has emerged as a viable option for CRT with physiological restoration of electrical 
synchrony by circumventing proximal conduction disease (2-4). The frequency in which His 
bundle pacing can correct left bundle branch block patterns (LBBB) in an unselected heart 
failure population is not known, and no prospective trials comparing BiV-CRT versus His bundle 
pacing in lieu of an LV lead for CRT (His-CRT) have been performed to date. The His Bundle 
Pacing versus Coronary Sinus Pacing for Cardiac Resynchronization Therapy (His-SYNC) pilot 
trial was an investigator-initiated, prospective, randomized controlled trial that aimed to assess 
the feasibility and efficacy of His-CRT as a first-line strategy compared to BiV-CRT. 
The study was conducted between May 2016 and June 2018 at 7 centers, and the 
University of Chicago served as the Study Coordinating Site (NCT0270045NCT02700425). 
Approval by the local institutional review board was obtained at each center, and patients were 
blinded to treatment allocation. Eligible patients aged >18 years meeting guideline indications 
for CRT were considered for inclusion. Patients were centrally randomized to His-CRT or 
coronary sinus lead for BiV-CRT with routine implantation techniques (1).  
As the trial sought to compare two strategies for CRT, crossover was mandated in 
patients assigned to His-CRT who did not achieve QRS narrowing by >20%, QRS width of ≤130 
ms, or who demonstrated high correction thresholds (>5V@1 ms). Crossover was permitted in 
patients randomized to BiV-CRT in whom an LV lead could not be placed. LV lead delivery into 
the anterior interventricular or middle cardiac veins was discouraged.  The primary outcomes of 
the trial were change in QRS duration, improvement in LVEF at 6 months, and time to 
cardiovascular hospitalization or death at 12 months. 
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Among 41 patients enrolled (64±13 yrs, 38% female, LVEF 28%, 65% with coronary 
artery disease, QRS width 168±18 ms [LBBB pattern=35, RBBB=2, paced=3]), 21 were 
randomized to His-CRT and 20 to BiV-CRT. One patient withdrew prior to implant in the BiV-
CRT group. Baseline characteristics revealed no differences except that LVEF was significantly 
lower among His-CRT (median 26.3% [21.3-28.3%] compared to BiV-CRT (30.5% [27.1-
33.9%], p=0.011). Crossover occurred in 48% of His-CRT and 26% of BiV-CRT. The most 
common reasons for crossover from His-CRT was inability to correct QRS (n=5) and suboptimal 
venous anatomy (n=4) in BiV-CRT.  
By intention-to-treat (ITT) analysis, significant reduction in QRS duration was observed 
with His-CRT (172±16 ms to 144±30 ms; p=0.002), but not BiV-CRT (165±18 ms to 152±30 
ms; p=0.11), although between-group differences were not significant (p=0.42). At a median 
follow-up of 6.2 months, improvements in LVEF relative to baseline were seen in both His-CRT 
(26.3% to 31.9%, p<0.001) and BiV-CRT patients (30.5% to 34.0%, p<0.001). His-CRT was not 
superior to BiV-CRT with regard to LVEF improvement (median +9.1% [5.0-14.4%] vs. +5.2 
[1.5-11.3%], p=0.33) or rate of echocardiographic response ≥5% (76% vs. 53%, p=0.13). Overall 
event rates were low (6 cardiovascular hospitalizations, 2 deaths), with no differences observed 
between groups (Figure). No His or LV lead dislodgements were observed during study follow-
up. 
QLV was reported in 20 of 24 patients receiving BiV across both arms (mean 131±29 
ms; mean QLV ratio 0.80±0.19).  Compared to those randomized to BiV-CRT, patients assigned 
to His-CRT had higher pacing thresholds (median 1.7 V versus 0.9 V, p=0.046), but not pulse 
width (median 1 ms versus 0.5 ms, p=0.45). His corrective capture thresholds remained stable in 
up to 12 months of follow-up. 
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In this first randomized pilot trial, His-CRT did not demonstrate significant 
improvements in electrocardiographic or echocardiographic parameters as compared to BiV-
CRT. This study was underpowered to detect differences less than 10% between groups and a 
type II error cannot be excluded. Importantly, ITT analysis in the presence of high crossover 
rates cannot directly assess treatment efficacy. Longer helices, deflectable sheaths with septal 
orientation, and intra-septal fixation are likely to improve His correction rates and stability of 
thresholds. In patients that required crossover from His-CRT, one-half of patients exhibited 
nonspecific intraventricular conduction delay (IVCD), which is unlikely to be corrected by His-
CRT (4).  Improved patient selection may decrease crossover rates and larger prospective studies 
may be useful to assess for smaller differences in effect size between CRT modalities. 
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Figure Legend 
Figure. Reduction in QRS duration and echocardiographic response by intention-to-treat 
analysis of patients randomized to BiV-CRT versus His-CRT. 
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